Personalized Tasty&Healthy whole-food diet for maintaining remission in children and adults with Crohn's disease: results from the MyTasty open-label trial

被引：0
|
作者：
Plotkin, L. [1 ,2 ]
Frutkoff, Y. Aharoni [1 ]
Shavit, Z. [1 ]
Focht, G. [1 ]
Livovsky, J. [1 ]
Buchuk, R. [1 ]
Lev-Zion, R. [1 ]
Ledder, O. [1 ]
Assa, A. [1 ]
Boneh, R. Sigall [3 ]
Weiss, B. [4 ]
Slae, M. [5 ]
Dotan, I [6 ]
Kierkus, J. [7 ]
Broide, E. [8 ]
Griffiths, A. [9 ]
Naftali, T. [10 ]
Aloi, M. [11 ]
Yerushalmy-Feler, A. [12 ]
Schwerd, T. [13 ]
Reifen, R. [2 ]
Turner, D. [1 ]
机构：
[1] Shaare Zedek Med Ctr, Juliet Keidan Inst Pediat Gastroenterol & Nutr, Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Inst Biochem Food Sci, Nutr Robert H Smith Fac Agr Food & Environm, Rehovot, Israel
[3] E Wolfson Med Ctr, Pediat Gastroenterol & Nutr Unit, Holon, Israel
[4] Sheba Med Ctr, Pediat Gastroenterol, Ramat Gan, Israel
[5] Pediat Gastroenterol Ctr, Hadassah Ein Kerem, Jerusalem, Israel
[6] Rabin Med Ctr, Div Gastroenterol, Petah Tiqwa, Israel
[7] Childrens Mem Hlth Inst, Pediat Gastroenterol Unit, Warsaw, Poland
[8] Assaf Harofeh Med Ctr, Pediat Gastroenterol Unit, Zerifin, Israel
[9] Hosp Sick Children, Pediat Gastroenterol, Toronto, ON, Canada
[10] Meir Hosp, Gastroenterol, Kefar Sava, Israel
[11] Sapienza Univ Rome, Dept Pediat Gastroenterol, Rome, Italy
[12] Tel Aviv Sourasky Med Ctr, Pediat Gastroenterol, Tel Aviv, Israel
[13] LMU Munchen, Dr Hauner Childrens Hosp, Munich, Germany
来源：
JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷
关键词：
D O I：
10.1093/ecco-jcc/jjae190.1267
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1093
引用
收藏
页码：i2009 / i2010
页数：2
相关论文
共 50 条
  • [41] First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial
    Jongsma, Maria M. E.
    Aardoom, Martine A.
    Cozijnsen, Martinus A.
    van Pieterson, Merel
    de Meij, Tim
    Groeneweg, Michael
    Norbruis, Obbe F.
    Wolters, Victorien M.
    van Wering, Herbert M.
    Hojsak, Iva
    Kolho, Kaija-Leena
    Hummel, Thalia
    Stapelbroek, Janneke
    van der Feen, Cathelijne
    van Rheenen, Patrick F.
    van Wijk, Michiel P.
    Teklenburg-Roord, Sarah T. A.
    Schreurs, Marco W. J.
    Rizopoulos, Dimitris
    Doukas, Michail
    Escher, Johanna C.
    Samsom, Janneke N.
    de Ridder, Lissy
    GUT, 2022, 71 (01) : 34 - 42
  • [42] TRIPLE COMBINATION THERAPY WITH VEDOLIZUMAB, ADALIMUMAB, AND METHOTREXATE IN PATIENTS WITH HIGH-RISK CROHN'S DISEASE: INTERIM ANALYSIS FROM THE OPEN-LABEL, PHASE 4 EXPLORER TRIAL
    Colombel, Jean Frederic
    Ungaro, Ryan C.
    Sands, Bruce E.
    Siegel, Corey A.
    Wolf, Douglas C.
    Valentine, John F.
    Kadali, Harisha
    Nazarey, Pradeep
    James, Alexandra
    Lasch, Karen
    Rana-Khan, Qasim
    GASTROENTEROLOGY, 2022, 162 (07) : S215 - S215
  • [43] Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial
    Petersenn, S.
    Salgado, L. R.
    Schopohl, J.
    Portocarrero-Ortiz, L.
    Arnaldi, G.
    Lacroix, A.
    Scaroni, C.
    Ravichandran, S.
    Kandra, A.
    Biller, B. M. K.
    ENDOCRINE, 2017, 57 (01) : 156 - 165
  • [44] Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial
    S. Petersenn
    L. R. Salgado
    J. Schopohl
    L. Portocarrero-Ortiz
    G. Arnaldi
    A. Lacroix
    C. Scaroni
    S. Ravichandran
    A. Kandra
    B. M. K. Biller
    Endocrine, 2017, 57 : 156 - 165
  • [45] Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn's Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study
    Wetwittayakhlang, Panu
    Verdon, Christine
    Starr, Michael
    Hahn, Gustavo Drugg
    Golovics, Petra A.
    Bessissow, Talat
    Afif, Waqqas
    Wild, Gary
    Bitton, Alain
    Lakatos, Peter L.
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2023, 34 (06): : 603 - 610
  • [46] LONG-TERM SAFETY AND TOLERABILITY OF ORAL TOFACITINIB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM A PHASE 2 OPEN-LABEL 48-WEEK EXTENSION STUDY
    Panes, Julian
    D'Haens, Geert R.
    Higgins, Peter D.
    Mele, Linda
    Moscariello, Michele
    Chan, Gary
    Wang, Wenjin
    Niezychowski, Wojciech
    Su, Chinyu
    Maller, Eric S.
    GASTROENTEROLOGY, 2017, 152 (05) : S599 - S599
  • [47] Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study
    Panes, Julian
    D'Haens, Geert R.
    Higgins, Peter D. R.
    Mele, Linda
    Moscariello, Michele
    Chan, Gary
    Wang, Wenjin
    Niezychowski, Wojciech
    Su, Chinyu
    Maller, Eric
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 49 (03) : 265 - 276
  • [48] Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2 open-label 48-week extension study
    Panes, J.
    D'Haens, G. R.
    Higgins, P. D. R.
    Mele, L.
    Moscariello, M.
    Chan, G.
    Wang, W.
    Niezychowski, W.
    Su, C.
    Maller, E.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S18 - S19
  • [49] EFFICACY AND SAFETY UP TO THREE YEARS OF RISANKIZUMAB TREATMENT IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE FORTIFY OPEN-LABEL LONG-TERM EXTENSION
    Ferrante, Marc
    Panaccione, Remo
    Colombel, Jean Frederic
    Dubinsky, Marla C.
    Hisamatsu, Tadakazu
    Lindsay, James O.
    Song, Alexandra P.
    Neimark, Ezequiel
    Zhang, Ying
    Kligys, Kristina
    Crowley, Jameson
    Duan, W. Rachel
    D'Haens, Geert
    GASTROENTEROLOGY, 2024, 166 (05) : S801 - S802
  • [50] Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial
    Jochen Schopohl
    Feng Gu
    Robert Rubens
    Luc Van Gaal
    Jérôme Bertherat
    Monica Ligueros-Saylan
    Andrew Trovato
    Gareth Hughes
    Luiz R. Salgado
    Marco Boscaro
    Rosario Pivonello
    Pituitary, 2015, 18 : 604 - 612
12345